cemiplimab


( Last Updated : July 21, 2021)
Generic Name:
cemiplimab
Project Status:
Pending
Therapeutic Area:
Basal cell carcinoma
Manufacturer:
Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Libtayo
Project Line:
Reimbursement Review
Project Number:
PC0260-000
Call for patient/clinician input closed:
Tumour Type:
Skin & Melanoma

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.